Monoclonal antibody and a method thereof

Abstract

The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.

That which is claimed is: 
     
       1. A method of treatment for an inflammatory disorder, the method comprising administering to a patient a therapeutically effective amount of a monoclonal anti-CD6 antibody that binds to domain 1 (D1) of CD6 without interfering with ALCAM binding, wherein the monoclonal antibody comprises heavy and light chain variable regions comprising amino acid sequences as set forth in SEQ ID NOs: 1 and 2, wherein the inflammatory disorder is multiple sclerosis, transplant rejection, rheumatoid arthritis or psoriasis. 
     
     
       2. The method of  claim 1 , wherein the therapeutically effective amount is a dose of 0.1 to 25 mg/Kg/week. 
     
     
       3. The method of  claim 1 , wherein the monoclonal anti-CD6 antibody is administered in combination with antigens capable of eliciting an anti-inflammatory immune response selected from a group comprising Glutamic acid decarboxylase (GAD) and Heat Shock Protein 60 (HSP60), Myelin Basic Protein (MBP) and Myelin oligodendrocyte glycoprotein (MOG). 
     
     
       4. The method of  claim 1 , wherein SEQ ID NOs: 1 and 2 are encoded by SEQ ID NOs: 3 and 4 respectively.